Pharming Group N.V. Files Form 6-K

Ticker: PHAR · Form: 6-K · Filed: 2025-03-04T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, press-release

TL;DR

Pharming Group N.V. dropped a 6-K filing on 3/4/25, likely with news in the attached press release.

AI Summary

Pharming Group N.V. filed a Form 6-K on March 4, 2025, to furnish a press release dated the same day. The filing does not contain specific financial figures or operational updates in the provided text, but indicates the submission of Exhibit 99.1, which is the press release itself.

Why It Matters

This filing serves as a notification to the SEC about the release of important company information, typically a press release, which could contain material updates for investors.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of a press release and does not contain inherently risky information.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to furnish a press release dated March 4, 2025, as Exhibit 99.1, to the U.S. Securities and Exchange Commission.

What is the filing date of this Form 6-K?

The filing date of this Form 6-K is March 4, 2025.

What is the SEC file number for Pharming Group N.V.?

The SEC file number for Pharming Group N.V. is 001-39822.

What is the address of Pharming Group N.V.'s principal executive offices?

The address of Pharming Group N.V.'s principal executive offices is Darwinweg 24, 2333 CR Leiden, The Netherlands.

What exhibit is furnished with this Form 6-K?

Exhibit 99.1, a press release of Pharming Group N.V. dated March 4, 2025, is furnished with this Form 6-K.

From the Filing

0001828316-25-000010.txt : 20250304 0001828316-25-000010.hdr.sgml : 20250304 20250304092419 ACCESSION NUMBER: 0001828316-25-000010 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250304 FILED AS OF DATE: 20250304 DATE AS OF CHANGE: 20250304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 25701811 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 pharminggroupreportsonresu.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated March 4, 2025. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s /Fabrice Chouraqui Name: Fabrice Chouraqui Title: CEO Date: March 4, 2025 Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025. In addition, shareholders also approved the proposal to approve certain components of the remuneration package of Mr. Chouraqui in his capacity as Executive Director and Chief Executive Officer. A recording of the webcast, presentation slides from today’s EGM, and more details regarding both agenda items are available on the Pharming website in the Investor Relations section. Dr. Richard Peters, Chairman of the Board of Directors, commented: “On behalf of the entire Board, we welcome Fabrice Chouraqui as our new Executive Director and Chief Executive Officer and we look forward to working with him to deliver on Pharming’s objectives and to further strengthen the company’s position in the rare disease market. We would also like to thank our outgoing Chief Executive Officer, Sijmen de Vries, for his signific

View on Read The Filing